Latest News about EDIT
Recent news which mentions EDIT
Could Editas Medicine Become the Next CRISPR Therapeutics?
January 21, 2024
From Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
January 17, 2024
From InvestorPlace
Down 88%, Could Editas Medicine Be a Good Investment Now?
January 15, 2024
From Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
From InvestorPlace
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
January 08, 2024
From Motley Fool
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
December 23, 2023
From Motley Fool
From MarketWatch
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
December 08, 2023
From MarketWatch
1 Promising Stock Down 66% That Could Skyrocket in 2024
December 05, 2023
Tickers
EDIT
From Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
From Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
November 29, 2023
From InvestorPlace
From InvestorPlace
The 3 Best Gene Editing Stocks on the Frontier of Medicine
November 20, 2023
From InvestorPlace
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
November 20, 2023
From Motley Fool
3 Long-Term Growth Stocks Analysts Are Bullish On
November 16, 2023
From InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
From InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 03, 2023
From Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
From Benzinga
Earnings Scheduled For November 3, 2023
November 03, 2023
From Benzinga
Sent Your Boss The Message Meant For Your Girlfriend On Instagram — Now You Can Save Your Bacon
November 01, 2023
From Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
From Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
From Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
October 18, 2023
From Motley Fool
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.